Amira Hovione and Zerion Pharma Expand Partnership to Accelerate Development of Dispersome® Technology

Hovione Farmaciência, S.A.(“HOVIONE”) and Zerion Pharma A/S (“ZERION”) today announced that they have expanded their part...

October 04, 2024 | Friday | News
Sygnature Discovery Appoints Amira Modi as New Chief Operating Officer and Board Member

World-leading contract research organization (CRO) Sygnature Discovery is delighted to announce the appointment of Amira Modi as its new Chief Operating ...

October 04, 2024 | Friday | News
Kailera Therapeutics Launches with Ambitious Plans for GLP-1 Drugs Targeting Obesity and Metabolic Conditions

In a year when metabolic diseases have drawn major investor interest, the newest player has big-name backing, a sizable war chest and veteran leadership. ...

October 02, 2024 | Wednesday | News
Thryv Therapeutics Secures FDA Orphan Drug Designation for LQT-1213 to Treat Long QT Syndrome

Thryv Therapeutics, a clinical stage biotech company dedicated to developing treatments for rare and life-threatening cardiovascular indications, announced...

October 02, 2024 | Wednesday | News
SIFI Secures European Patent for Innovative Polihexanide Formulation in Germany Eye Infection Treatment

The company's intellectual property ("IP") covers the formulation and method of use of polihexanide in the treatment of acanthamoeba keratitis and fung...

September 30, 2024 | Monday | News
Thermo Fisher Scientific Expands OSD Capabilities with $22 Million Investment to Accelerate Drug Development

To provide flexible and innovative solutions for early development challenges commonly faced by biotech and pharmaceutical companies, Thermo Fisher Scien...

September 27, 2024 | Friday | News
Roche Announces Positive Phase III Results for Gazyva/Gazyvaro in Lupus Nephritis, Demonstrating Superiority Over Standard Therapy Alone

Roche announced positive topline results from the Phase III REGENCY study, which evaluated Gazyva®/Gazyvaro® (obinutuzumab) in people with active...

September 26, 2024 | Thursday | News
European Commission Approves Junshi Biosciences' Toripalimab for Two Key Cancer Indications

Shanghai Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of nov...

September 25, 2024 | Wednesday | News
Nxera Pharma Secures Japanese Approval for QUVIVIQ™ to Treat Insomnia Based on Positive Phase 3 Trial Results

The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3...

September 24, 2024 | Tuesday | News
Takeda Receives Japanese Approval for FRUZAQLA® (Fruquintinib) in Metastatic Colorectal Cancer Treatment

— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — &md...

September 24, 2024 | Tuesday | News
EMA's CHMP Recommends Approval of Intas Pharmaceuticals' HETRONIFLY® (Serplulimab) for Extensive-Stage Small Cell Lung Cancer

Intas Pharmaceuticals announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive op...

September 23, 2024 | Monday | News
AbbVie’s Mirvetuximab Soravtansine Receives Positive CHMP Recommendation for Platinum-Resistant Ovarian Cancer Treatment in EU

AbbVie announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommen...

September 23, 2024 | Monday | News
Thermo Fisher's PPD Clinical Research Expands to GoCo Health Innovation City in Sweden

The PPD clinical research business joins GoCo Health Innovation City in Gothenburg, Sweden The PPD™ clinical research business of Thermo Fisher Sc...

September 19, 2024 | Thursday | News
Vidac Pharma Secures Broad U.S. Patent for Pioneering Cancer Treatment Mode of Action

Vidac Pharma Holdings Plc., a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments,  announces that the U...

September 19, 2024 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close